{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T01:41:25Z","timestamp":1771378885183,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12325-016-0423-5","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T14:39:42Z","timestamp":1476715182000},"page":"2110-2121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["\u03b11-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?"],"prefix":"10.1007","volume":"33","author":[{"given":"Claus G.","family":"Roehrborn","sequence":"first","affiliation":[]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[]},{"given":"Ferdinando","family":"Fusco","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"issue":"5","key":"423_CR1","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.urology.2011.11.084","volume":"79","author":"BS Malaeb","year":"2012","unstructured":"Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000\u20132008). Urology. 2012;79(5):1111\u20136.","journal-title":"Urology"},{"key":"423_CR2","unstructured":"Gravas S, Bach T, Bachmann A, et al. Guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Arnheim: European Association of Urology; 2014."},{"issue":"Suppl 1","key":"423_CR3","first-page":"S9","volume":"11","author":"H Lepor","year":"2009","unstructured":"Lepor H. Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol. 2009;11(Suppl 1):S9\u201313.","journal-title":"Rev Urol"},{"key":"423_CR4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ncpuro0836","volume":"4","author":"KE Andersson","year":"2007","unstructured":"Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4:368\u201378.","journal-title":"Nat Clin Pract Urol"},{"issue":"2","key":"423_CR5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-3565(24)29397-6","volume":"298","author":"MT Piascik","year":"2001","unstructured":"Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther. 2001;298(2):403\u201310.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"423_CR6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5213\/inj.2015.19.3.190","volume":"19","author":"YW Kim","year":"2015","unstructured":"Kim YW, Park J, Chung H, et al. The effectiveness of silodosin for nocturnal polyuria in elderly men with benign prostatic hyperplasia: a multicenter study. Int Neurourol J. 2015;19(3):190\u20136.","journal-title":"Int Neurourol J"},{"key":"423_CR7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1476-5381.1996.tb15742.x","volume":"119","author":"K Nasu","year":"1996","unstructured":"Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of \u03b11-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and nonhypertrophied tissue. Br J Pharmacol. 1996;119:797\u2013803.","journal-title":"Br J Pharmacol"},{"key":"423_CR8","first-page":"291","volume":"4","author":"M Rossi","year":"2010","unstructured":"Rossi M, Roumegu\u00e8re T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010;4:291\u20137.","journal-title":"Drug Des Devel Ther"},{"key":"423_CR9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1517\/14656566.2012.714368","volume":"13","author":"NI Osman","year":"2012","unstructured":"Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F. Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012;13:2085\u201396.","journal-title":"Expert Opin Pharmacother"},{"key":"423_CR10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0026-895X(25)10243-5","volume":"48","author":"K Shibata","year":"1995","unstructured":"Shibata K, Foglar R, Horie K, et al. KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995;48:250\u20138.","journal-title":"Mol Pharmacol"},{"key":"423_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bju.12712","volume":"114","author":"G Novara","year":"2014","unstructured":"Novara G, Chapple CR, Montorsi F. A pooled analysis of individual patient data from registrational trials of\u00a0silodosin\u00a0in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int. 2014;114:427\u201333.","journal-title":"BJU Int"},{"key":"423_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1248\/yakushi.126.209","volume":"126","author":"S Tatemichi","year":"2006","unstructured":"Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006;126:209\u201316.","journal-title":"Yakugaku Zasshi"},{"key":"423_CR13","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1016\/j.juro.2009.08.030","volume":"182","author":"Y Matsukawa","year":"2009","unstructured":"Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy\u00a0of\u00a0silodosin\u00a0for\u00a0relieving\u00a0benign\u00a0prostatic\u00a0obstruction:\u00a0prospective\u00a0pressure\u00a0flow\u00a0study. J Urol. 2009;182:2831\u20135.","journal-title":"J Urol"},{"key":"423_CR14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/nau.20802","volume":"29","author":"T Yamanishi","year":"2010","unstructured":"Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558\u201362.","journal-title":"Neurourol Urodyn"},{"key":"423_CR15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","volume":"69","author":"F Fusco","year":"2016","unstructured":"Fusco F, Palmieri A, Ficarra V, et al. \u03b11-blockers\u00a0improve\u00a0benign\u00a0prostatic\u00a0obstruction\u00a0in\u00a0men\u00a0with\u00a0lower urinary tract symptoms: a\u00a0systematic review\u00a0and\u00a0meta-analysis\u00a0of\u00a0urodynamic\u00a0studies. Eur Urol. 2016;69:1091\u2013101.","journal-title":"Eur Urol"},{"key":"423_CR16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342\u201352.","journal-title":"Eur Urol"},{"issue":"1","key":"423_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","volume":"36","author":"B Djavan","year":"1999","unstructured":"Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36(1):1\u201313.","journal-title":"Eur Urol"},{"key":"423_CR18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/j.1464-410X.2011.10233.x","volume":"108","author":"HJ Yu","year":"2011","unstructured":"Yu HJ, Lin AT, Yang SS, et al. Non-inferiority of\u00a0silodosin\u00a0to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int. 2011;108:1843\u20138.","journal-title":"BJU Int"},{"key":"423_CR19","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98:1019\u201324.","journal-title":"BJU Int"},{"key":"423_CR20","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/ijcp.12135","volume":"67","author":"U Capitanio","year":"2013","unstructured":"Capitanio U, Salonia A, Briganti A, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013;67:544\u201351.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"423_CR21","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","volume":"181","author":"LS Marks","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181(6):2634\u201340.","journal-title":"J Urol"},{"issue":"5","key":"423_CR22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00345-013-1228-7","volume":"32","author":"A Eisenhardt","year":"2014","unstructured":"Eisenhardt A, Schneider T, Cruz F, Oelke M. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32(5):1119\u201325.","journal-title":"World J Urol"},{"issue":"2","key":"423_CR23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1742-1241.2012.03012.x","volume":"67","author":"F Montorsi","year":"2013","unstructured":"Montorsi F, Mercadante D. Diagnosis of BPH and treatment of LUTS among GPs: a European survey. Int J Clin Pract. 2013;67(2):114\u20139.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"423_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0090-4295(99)80409-9","volume":"47","author":"CG Roehrborn","year":"1996","unstructured":"Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: a one-study of terazosin vs placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 1996;47(2):159\u201368.","journal-title":"Urology"},{"issue":"10","key":"423_CR25","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1532-5415.2000.tb02608.x","volume":"48","author":"M Miller","year":"2000","unstructured":"Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc. 2000;48(10):1321\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"423_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2011.05.065","volume":"61","author":"V Kupelian","year":"2012","unstructured":"Kupelian V, Wei JT, O\u2019Leary MP, Norgaard JP, Rosen RC, McKinlay JB. Nocturia and quality of life: results from the Boston area community health survey. Eur Urol. 2012;61(1):78\u201384.","journal-title":"Eur Urol"},{"issue":"10","key":"423_CR27","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","volume":"62","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of \u03b1-adrenergic blockers for symptoms related tobenign prostatic hyperplasia. Int J Clin Pract. 2008;62(10):1547\u201359.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"423_CR28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2005.12.032","volume":"49","author":"J Irani","year":"2006","unstructured":"Irani J. Are all\u00a0alpha-blockers\u00a0created\u00a0the\u00a0same? Eur Urol. 2006;49(3):420\u20132.","journal-title":"Eur Urol"},{"issue":"9","key":"423_CR29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1517\/14740338.2014.936376","volume":"13","author":"M Oelke","year":"2014","unstructured":"Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of \u03b11-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13(9):1187\u201397.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"423_CR30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bju.12906","volume":"115","author":"G Novara","year":"2015","unstructured":"Novara G, Chapple CR, Montorsi F. Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH):\u00a0subgroup\u00a0analyses of efficacy and safety data. BJU Int. 2015;115(5):802\u201314.","journal-title":"BJU Int"},{"key":"423_CR31","doi-asserted-by":"crossref","unstructured":"Montorsi F, Gandaglia G, Chapple C, Cruz F, Desgrandchamps F, Llorente C. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: a European phase IV clinical study (SiRE study). Int J Urol. 2016. 23(7):572\u20139.","DOI":"10.1111\/iju.13088"},{"issue":"4","key":"423_CR32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00345-012-0944-8","volume":"31","author":"G Novara","year":"2013","unstructured":"Novara G, Tubaro A, Sanseverino R, et al. Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31(4):997\u20131008.","journal-title":"World J Urol"},{"issue":"11","key":"423_CR33","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.clinthera.2004.11.006","volume":"26","author":"FC Lowe","year":"2004","unstructured":"Lowe FC. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004;26(11):1701\u201313.","journal-title":"Clin Ther"},{"issue":"12","key":"423_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2490-12-29","volume":"19","author":"K Sakata","year":"2012","unstructured":"Sakata K, Morita T. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia. BMC Urol. 2012;19(12):29. doi: 10.1186\/1471-2490-12-29 .","journal-title":"BMC Urol"},{"issue":"6","key":"423_CR35","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11(6):1554\u201366.","journal-title":"J Sex Med"},{"issue":"Suppl 1","key":"423_CR36","first-page":"S14","volume":"11","author":"SA Kaplan","year":"2009","unstructured":"Kaplan SA. Side effects\u00a0of\u00a0alpha-blocker\u00a0use:\u00a0retrograde\u00a0ejaculation. Rev Urol. 2009;11(Suppl 1):S14\u20138.","journal-title":"Rev Urol"},{"issue":"3","key":"423_CR37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000052361","volume":"37","author":"P Kerrebroeck van","year":"2000","unstructured":"van Kerrebroeck P, et al. Efficacy and safety of a new prolonged release formulation of alfuzosin 10\u00a0mg once daily versus alfuzosin 2.5\u00a0mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol. 2000;37(3):306\u201313.","journal-title":"Eur Urol"},{"issue":"3","key":"423_CR38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1046\/j.1464-410x.2001.02032.x","volume":"87","author":"RS Kirby","year":"2001","unstructured":"Kirby RS, Andersen M, Gratzke P, Dahlstrand C, H\u00f8ye K. A\u00a0combined\u00a0analysis\u00a0of\u00a0double-blind\u00a0trials\u00a0of the\u00a0efficacy\u00a0and\u00a0tolerability\u00a0of\u00a0doxazosin-gastrointestinal therapeutic\u00a0system,\u00a0doxazosin\u00a0standard\u00a0and\u00a0placebo\u00a0in\u00a0patients\u00a0with\u00a0benign\u00a0prostatic\u00a0hyperplasia. BJU Int. 2001;87(3):192\u2013200.","journal-title":"BJU Int"},{"issue":"3","key":"423_CR39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4103\/0974-7796.134254","volume":"6","author":"MS Griwan","year":"2014","unstructured":"Griwan MS, Karthikeyan YR, Kumar M, Singh BJ, Singh SK Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia. Urol Ann. 2014;6(3):181\u20136.","journal-title":"Urol Ann"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0423-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:36:14Z","timestamp":1749656174000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0423-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["423"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0423-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}